Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

NCT05512481 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Acral Melanoma
Temozolomide
Apatinib
Camrelizumab
Neoadjuvant
Pathological Response

Interventions

DRUG: Camrelizumab

Sponsor

Peking University Cancer Hospital & Institute